|
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
PERSPECTIVE THERAPEUTICS, INC. | ||
Date: March 25, 2024 | By: | /s/ Johan (Thijs) Spoor |
Johan (Thijs) Spoor | ||
Chief Executive Officer |
Document And Entity Information |
Mar. 25, 2024 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | Perspective Therapeutics, Inc. |
Document, Type | 8-K |
Document, Period End Date | Mar. 25, 2024 |
Entity, Incorporation, State or Country Code | DE |
Entity, File Number | 001-33407 |
Entity, Tax Identification Number | 41-1458152 |
Entity, Address, Address Line One | 2401 Elliott Avenue, Suite 320 |
Entity, Address, City or Town | Seattle |
Entity, Address, State or Province | WA |
Entity, Address, Postal Zip Code | 98121 |
City Area Code | 206 |
Local Phone Number | 676-0900 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | CATX |
Security Exchange Name | NYSE |
Entity, Emerging Growth Company | false |
Amendment Flag | false |
Entity, Central Index Key | 0000728387 |
5@ZJJ+G0 $ #P" / " 5,0 !X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " 9BGE8)!Z;HJT #X 0 &@ M@ ' $0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 9 MBGE899!YDAD! #/ P $P @ &E$@ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" #O$P ! end
9<6N\A5LD(V7^$EAG+PFB"-&?PJJ M,#T<\"Q;YX<715DB4(ESQ&W"&4VHPL^R1PQJ00DK(68&.6(U%J!5P"_&(A>? MZMQ:/,WGI4^S'GP=ED,IUR#>Q-58Q=73AF2-0;9KM6=3JDIS9A/$$:.I(-H3 MF.RR&2\+O=)RQ^H\;),ER1=@R/.J8$[7@(<,Q +%^"KX1BTQCE8DWQD7@4JT M(YY]#.I4!_871A8ES$K+G6HVP,X$84.<8=L_P*R6 6?B=FXR]$42<($SN!RLUWE=\&-4P.T-6*K3]4J'"C+*2H^.''&_VE:S$N?%)').?9:7$K4]* M6%EG5K+\YI,LM4Z=E22_>RB)R1JT$N2#AX)4VI!6JMQYJ$J%Z6F7H'F2KYH= M5SL9/$E4JZU>.RD\R58M[&4[/3Q)5^M<;3LQ/$E/;4UT.U$\R53?YM;;2>-) MMEJ]36 GA2=9:L46A9T.GB2G]?LB=G)XE95:[,+8.6:>I*45.T!V.GB2EUKL M.IWM.,07DF##/SZ=2O2/_ELOWOD74$L#!!0 ( !F*>5B[CX7DFA$ (QG M 2 :7-R,C R-# S,C5?.&LN:'1M[3UKE]JXDI\GOT++[$RZS\%@ ]U- MTX][""$9;M*/ ^3>V?VR1]@"-#$V(\G=L+_^5DDVVHYX3T=')F)H!*4JG> M52I[3O\QF_CDA@G)P^#LK5.RWQ(6N*''@]'9VV:OU>F\_19 M8:S4M%$NW][>EFZKI5",RL[Q\7%YAC % ]00;)@!G V$KT$KMGU8AM$$$ <\ MOH#-PIG!!#2@W)592,G LAF%.IIM?E&U&HEGD@%0U >.V80FP'RF+-@Z,R%!A0<^#]CO[[J?RTK00 Y#,:$*J MK.0>67;>J MSF)3 /VZF: XFMHR_S1W[5>Q*H<+"H9!$$WRU_&4**OYE)4!R (H)KB;S(ND MA4-+X@^I'.A9R4B&]I$2;+21]L=E&%\>:Q.<4TT=+86("/T-B.@11,2V;"=% M9:FF(E]L<"2#^1H_LD*#PP,J%T+#95BK.$?;Q,Q )!. R"N4S.=! $%TY89G;W_<' X^DB4WG*18?#\&SW(- MQAVX>(SG,PP&LI(FK1&ETUQQP($,L!M&@1+S_)7CP#0SA #H(O3F1:NZ#W X!TI+\_UF#./94 MG1#]PY!.N#]OD%__C$)UTN<3)LDENR7=<$(#\^,)F5(/G5Z#V#P@=LGAP0D! M9LA0- B-5'@"1/'X3;*3Q^74I[ HF$M6 #3XK($(,1%_YI[' O,90"Z-035' MF:DNNDC N'@D_CLQJH<'!;.A]27[+2< M6>^AZ[<#X-J\!1L(ZG> 1;-/;)[>YZAP;L.?HTJ]6C]:V^R-_B5]-/#D#.65 M2?B.YK$AM4H# D3[K\98AP(@0%8B027PM85X%*W=64'RR=1GP%2S0691_5V& MD3!?M5]OQ,?4B"?'7 PR? I\RAY]=3+BEKO^%&@3 M>HNO8,F$>@^*<(YX6785J)K,7(XM4VP"8CBVT7^Y0S- "NO$G(MB13.2V. M99!;9%Y*?--Z\79%(]Z>+-5(:Y'^>D,%IX$">8#XPC^94#'B00.'"^>__NP< MVB=W[;.R37J7^H9=\( 6]?DH:+A =B:R^YX.SK]<=OKM]Z37;_;;O=/RX'PG M6/3:K2_=3K_3[I'FY7O2_KWU6_/R8YNTKBXN.KU>Y^KRB:AM8L/=J/V[V?NM M<_FQ?W59).]+K1*IV >UX_N@\^QR,1;)-F/&1V,%1GHZ RL;^FAD?[;UGQ,R MH.[7D0!_[%FK0[?<4V.T[?8O !<*D&]C@4](O#&I3A6QM2E)'2L9?*!/6'4G M.Y7T#U?="_(P<_\^="/T)L:-)E;>.=;KU:U/1@JR1OX^DD%6#[A&*9(Y(XD/ M25*G)/$Q29HWWY'(_+6*^60Y>KQ! $O5;5_V2;=]?=7M[\PN74-L%<$,HD+2 M8RYFK,2IDE 0YV#/V]\97N&0J#%#E"+!%8<-VA!CTV#$2--5!(:=XVIM)_;S M6Y(!8P\\;)=-(7XG>\EW1B'V8%(1=@,3B=##S-MOW,LTF>($FB'5\%"0"- M/3J?P[(LR#-=USKJ:9M@:&G#JE6-Y045[IA4#HH$=WBL.?OAZ)[?T55JCQ2] M1^0S73;B$HM?ZA)&4D)B'!V(D)RBA;EAD)A"DCIED>*N+)).X);RA68'&K?7 MGE$P,'@$HWC)H0B5I <'P#3$(Y"= $-JE_6 M6!LU!&T*!;@#77WN(73+%-5:H9?2R@/;.!CFTUNP^EOT#TE25MZ#B%G[/HFY M2JL/W& J:3#7' M >@ EQ'2:G3?ZWQ@L<4T;- MT_[GI:@K4+<53B9 +]5#KN2$H[W1YI3Z9^.&=BEY3,6@QR&98V M$#2V F_@;^.KRSJ8^);)P EY@DD9__69!\Q9 M.I:ZR2DK-=LA;=_G<$K2A"PW8D72BSB8XVK%SG,VQ0>6Y3*XM.#CE>B'MT$* MDP-35694*3\W0KK?E@\.X6* !.KQ'+P.@:[^__)I-LX]=C2MCNM.Q?E+0Y0=Z=]>?'Q,5J\%R F?4I^T M9\R-=*I]-01[S.03/=NN#@?L),C/[]>/?$MR+(L12(Y??ZY7G*,3^%T2Q7PV M'4.B3@(=R!0)2((?H3,CD-U1T"2/- P_0+C6(39F GS7(I:E3MTV1&@P3\:&H0^;XSR,6SBF;++QS?7NL3%[1GZT\/( 4Q4L MT,_6 ^]M#K&PZC63M>L:X6T>DJS1HVAN<(M$@BT;IJA#[D>>QP2?@S#T!Q2X M"<>=I>WPOP57($"8DT=!G,+)5%/2X1'RX_BH5CMY6#DLIM BR?F6%(H/!:1) MGXI,4[>>W0ADJE8YB(5^Y=81+QOWG"/2^M EE:I= L#]Q\8AZ[="C^J1^Z$6 MWU(M>J'/79"%8'0!AA@V]=,Z47^!.K$\$7A/ 1(CB?Y:8.>*?_<&J> M5=D;[-]/80SL#Y5YQ2K3D3)B(E]QCNQ7I#A59M7VW/LI3@S[:,5YB?E@*A8U M"1H3D.)-\]KVM &*$S:@W WCHS^F&] =$]>G4CZYZ._\DF+K^NSGH9>S(WH)BI*XRQO2WGPR M"/V]QY3C=\&H2GTGC$J:[[1 J/*J:G'9P]D*JG0O=K_G7IE IR0_V(D?^V2[;MD"D^#S9> M-*#]=0JQC?P[L4W 2WFOW?G]ZG]GP$W9'=>$S CN9E_1X^ MD?4D%LUV-#MQC\+E__3:>60G3?TW#5[!K65FET[@8:C/\.%C5U]DP/!7L)U, MM\^MW#)P26A ($_ %49D),);-<:,88HW#U02CPUY8)JM3976/B#K#X8LGP>I MDCT\Y]&)KM0FP+ -,'&*;=IX@6;2CLK JN2LE?>0R6)13$&6\U++EOX>-Y Z M<,YNV][ G&=-C4T;1[+51[U3RVR4SHJ=N[+BETC^K/H,MR@$7NGG:A=?N[X; M@^XP'])"T)T@U$EB))F& B[%EX3XEA*N$T?S2#/R2^_ESW'S6PY;(ZL#. Z, M"';#)